Targeting of mitomycin C to the liver by the use of asialofetuin as a carrier.
Desialylated fetuin (asialofetuin) was adopted as a carrier for introducing drugs in parenchymal liver cells. Mitomycin C, as a model guest-compound, was covalently attached to asialofetuin through a spacer of the succinyl group. The asialofetuin-mitomycin C conjugate contained 4.4 w/w% of mitomycin C and liberated it gradually at physiological conditions (t1/2 = 37 h). The survival time of the conjugate in rat blood circulation was significantly smaller than that of the non-desialylated fetuin conjugate; the elimination half-life was 7.3 min after intravenous injection. At 30 min after injection of the conjugate in rats, 40% of the dose was present in the liver. Parenchymal cells in the liver selectively took up the conjugate, which was highly distributed to the lysosomal fraction in the cell. The greater uptake of the conjugate by hepatocytes reflected the increased excretion in the bile; totally 10.4% of the dose was recovered.
Kaneo
Y
Y
Department of Pharmacy & Pharmaceutical Sciences, Fukuyama University, Japan.
Tanaka
T
T
Iguchi
S
S
D000818:Animals; D001212:Asialoglycoproteins; D001646:Bile / Q000378:metabolism; D004337:Drug Carriers; D060748:Fetuins; D008099:Liver / Q000378:metabolism*; D008297:Male; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage* / Q000493:pharmacokinetics; D051381:Rats; D011919:Rats, Inbred Strains; D000509:alpha-Fetoproteins / Q000008:administration & dosage* / Q000493:pharmacokinetics
D001212:Asialoglycoproteins; D004337:Drug Carriers; D060748:Fetuins; D008937:Mitomycins; D000509:alpha-Fetoproteins; C017029:asialofetuin; D016685:Mitomycin